Ian Michael Estepan
CIK: 0001836254
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Sarepta Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Sep 4, 2026SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct24.8K shares at avg. $22.22$551K - Mar 11, 2026SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct1.1K shares at avg. $17.03$19K - Mar 9, 2026SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct583 shares at avg. $16.95$10K - Mar 9, 2026SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct1K shares at avg. $16.95$18K - Mar 2, 2026SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct3.3K shares at avg. $16.20$53K - Mar 2, 2026SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct875 shares at avg. $16.20$14K - Mar 1, 2026SRPT
Sarepta Therapeutics, Inc.
Exercise(M)Direct8.1K shares- - Feb 26, 2026SRPT
Sarepta Therapeutics, Inc.
Exercise(M)Direct5.4K shares at avg. $13.71$74K - Feb 26, 2026SRPT
Sarepta Therapeutics, Inc.
Exercise(M)Direct2.1K shares at avg. $13.71$28K - Feb 25, 2026SRPT
Sarepta Therapeutics, Inc.
Award(A)DirectPerformance Stock Units
1.9K shares- - Dec 16, 2025SRPT
Sarepta Therapeutics, Inc.
Sale(S)Direct13.2K shares at avg. $22.31$294K - Sep 3, 2025SRPT
Sarepta Therapeutics, Inc.
Award(A)Direct50K shares- - Sep 3, 2025SRPT
Sarepta Therapeutics, Inc.
Award(A)Direct93.9K shares- - Aug 5, 2025SRPT
Sarepta Therapeutics, Inc.
Award(A)DirectPerformance Stock Units
6.3K shares- - Mar 10, 2025SRPT
Sarepta Therapeutics, Inc.
Award(A)Direct8.3K shares- - Mar 10, 2025SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct2.9K shares at avg. $100.13$289K - Mar 10, 2025SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct1.1K shares at avg. $100.13$105K - Mar 7, 2025SRPT
Sarepta Therapeutics, Inc.
Exercise(M)Direct5.5K shares- - Mar 7, 2025SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct9.1K shares at avg. $103.70$943K - Mar 7, 2025SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct585 shares at avg. $103.70$61K - Mar 6, 2025SRPT
Sarepta Therapeutics, Inc.
Exercise(M)Direct17.5K shares- - Mar 4, 2025SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct1.4K shares at avg. $101.34$139K - Mar 3, 2025SRPT
Sarepta Therapeutics, Inc.
Tax Payment(F)Direct557 shares at avg. $103.77$58K - Feb 11, 2025SRPT
Sarepta Therapeutics, Inc.
Award(A)DirectPerformance Restricted Stock Units
3.5K shares- - Jan 29, 2025SRPT
Sarepta Therapeutics, Inc.
Exercise(M)Direct1.5K shares at avg. $12.00$18K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 4, 2026 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 24,799 | $22.22 | $551,034 | Direct |
| Mar 11, 2026 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 1,097 | $17.03 | $18,682 | Direct |
| Mar 9, 2026 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 583 | $16.95 | $9,882 | Direct |
| Mar 9, 2026 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 1,036 | $16.95 | $17,560 | Direct |
| Mar 2, 2026 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 3,301 | $16.20 | $53,476 | Direct |
| Mar 2, 2026 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 875 | $16.20 | $14,175 | Direct |
| Mar 1, 2026 | SRPT Sarepta Therapeutics, Inc. | Exercise(M) | 8,125 | - | $0 | Direct |
| Feb 26, 2026 | SRPT Sarepta Therapeutics, Inc. | Exercise(M) | 5,381 | $13.71 | $73,774 | Direct |
| Feb 26, 2026 | SRPT Sarepta Therapeutics, Inc. | Exercise(M) | 2,069 | $13.71 | $28,366 | Direct |
| Feb 25, 2026 | SRPT Sarepta Therapeutics, Inc. | Award(A) Performance Stock Units | 1,875 | - | - | Direct |
| Dec 16, 2025 | SRPT Sarepta Therapeutics, Inc. | Sale(S) | 13,187 | $22.31 | $294,202 | Direct |
| Sep 3, 2025 | SRPT Sarepta Therapeutics, Inc. | Award(A) | 50,000 | - | - | Direct |
| Sep 3, 2025 | SRPT Sarepta Therapeutics, Inc. | Award(A) | 93,875 | - | - | Direct |
| Aug 5, 2025 | SRPT Sarepta Therapeutics, Inc. | Award(A) Performance Stock Units | 6,250 | - | - | Direct |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | Award(A) | 8,276 | - | - | Direct |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 2,890 | $100.13 | $289,376 | Direct |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 1,051 | $100.13 | $105,237 | Direct |
| Mar 7, 2025 | SRPT Sarepta Therapeutics, Inc. | Exercise(M) | 5,500 | - | - | Direct |
| Mar 7, 2025 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 9,094 | $103.70 | $943,048 | Direct |
| Mar 7, 2025 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 585 | $103.70 | $60,665 | Direct |
| Mar 6, 2025 | SRPT Sarepta Therapeutics, Inc. | Exercise(M) | 17,500 | - | - | Direct |
| Mar 4, 2025 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 1,370 | $101.34 | $138,836 | Direct |
| Mar 3, 2025 | SRPT Sarepta Therapeutics, Inc. | Tax Payment(F) | 557 | $103.77 | $57,800 | Direct |
| Feb 11, 2025 | SRPT Sarepta Therapeutics, Inc. | Award(A) Performance Restricted Stock Units | 3,500 | - | - | Direct |
| Jan 29, 2025 | SRPT Sarepta Therapeutics, Inc. | Exercise(M) | 1,533 | $12.00 | $18,396 | Direct |
1-25 of 29 transactions
About Estepan Ian Michael
Estepan Ian Michael (SEC CIK 0001836254) files insider reports with the SEC as Chief Operating Officer of Sarepta Therapeutics, Inc. (SRPT).
Signal8 holds 17 ownership filings by Estepan Ian Michael, all Form 4s, filed between Sep 3, 2024 and Sep 8, 2026. Those filings report 29 transactions, from Aug 30, 2024 to Sep 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Estepan Ian Michael's filings is in CAMBRIDGE, MA.
Recent filings by Estepan Ian Michael
- Sep 4, 2026: Tax withholding of SRPT shares (Form 4, code F).
- Mar 11, 2026: Tax withholding of SRPT shares (Form 4, code F).
- Mar 9, 2026: Tax withholdings of SRPT shares (2 lines, Form 4, code F).
- Mar 2, 2026: Tax withholdings of SRPT shares (2 lines, Form 4, code F).
- Mar 1, 2026: Option exercise of SRPT shares (Form 4, code M).
Other insiders filing for Sarepta Therapeutics, Inc. (SRPT)
- Wong Ryan Ho-Yan, Chief Financial Officer
- Rothfuss Cristin, EVP, General Counsel
- Rodino-Klapac Louise, President, R&D and Tech Ops
- SEVERINO MICHAEL, Chief Executive Officer
- Boor Kathryn Jean, Director
- Mayo Stephen, Director